XML 38 R23.htm IDEA: XBRL DOCUMENT v3.19.1
Goodwill and Intangible Assets, Net
 12 Months Ended
Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net
Goodwill and Intangible Assets, Net
Changes in the carrying amount of goodwill were as follows:
(In millions)
U.S. Pharmaceutical and Specialty Solutions
 
European Pharmaceutical Solutions
 
Medical-Surgical Solutions
 
Other
 
Total
Balance, March 31, 2017
$
3,391

 
$
2,789

 
$
2,069

 
$
2,337

 
$
10,586

Goodwill acquired
657

 
26

 
—

 
1,024

 
1,707

Acquisition accounting, transfers and other adjustments
4

 
—

 
1

 
34

 
39

Goodwill impairment (1)
—

 
(1,283
)
 
—

 
(455
)
 
(1,738
)
Goodwill disposed (2)
(37
)
 
(11
)
 
—

 
(124
)
 
(172
)
Amount reclassified to assets held for sale
—

 
(2
)
 
—

 
—

 
(2
)
Foreign currency translation adjustments, net
95

 
331

 
—

 
78

 
504

Balance, March 31, 2018
4,110

 
1,850

 
2,070

 
2,894

 
10,924

Goodwill acquired
17

 
52

 
360

 
13

 
442

Goodwill impairment (1)
—

 
(1,776
)
 
—

 
(21
)
 
(1,797
)
Acquisition accounting, transfers and other adjustments
13

 
(5
)
 
21

 
6

 
35

Foreign currency translation adjustments, net
(62
)
 
(121
)
 
—

 
(63
)
 
(246
)
Balance, March 31, 2019
$
4,078

 
$
—

 
$
2,451

 
$
2,829

 
$
9,358


(1)
In 2019 and 2018, goodwill impairment charges from our international businesses were translated at average exchange rates during the corresponding period and accumulated goodwill impairment losses described below were translated at year-end exchange rates.
(2)
2018 Other amount primarily represents goodwill disposal associated with the sale of our EIS business. Refer to Financial Note 6, “Divestitures” for more information.

As of March 31, 2019, accumulated goodwill impairment losses were $2,943 million in our European Pharmaceutical Solutions segment and $461 million in Other. As of March 31, 2018, accumulated goodwill impairment losses were $1,299 million in our European Pharmaceutical Solutions segment and $456 million in Other. Refer to Financial Note 2 “Goodwill Impairment Charges,” for more information on the impairment charges recorded in 2019 and 2018.
Information regarding intangible assets is as follows:
 
March 31, 2019
 
March 31, 2018
(Dollars in millions)
Weighted
Average
Remaining
Amortization
Period
(Years)
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships
12
 
$
3,818

 
$
(1,801
)
 
$
2,017

 
$
3,619

 
$
(1,550
)
 
$
2,069

Service agreements
11
 
1,017

 
(430
)
 
587

 
1,037

 
(386
)
 
651

Pharmacy licenses
26
 
513

 
(209
)
 
304

 
684

 
(196
)
 
488

Trademarks and trade names
13
 
887

 
(232
)
 
655

 
932

 
(187
)
 
745

Technology
4
 
141

 
(94
)
 
47

 
147

 
(84
)
 
63

Other
5
 
288

 
(209
)
 
79

 
262

 
(176
)
 
86

Total
 
 
$
6,664

 
$
(2,975
)
 
$
3,689

 
$
6,681

 
$
(2,579
)
 
$
4,102

Amortization expense of intangible assets was $485 million, $503 million and $444 million for 2019, 2018 and 2017. Estimated annual amortization expense of intangible assets is as follows: $419 million, $400 million, $368 million, $265 million and $249 million for 2020 through 2024, and $1,988 million thereafter. All intangible assets were subject to amortization as of March 31, 2019 and 2018.

Refer to Financial Note 3, “Restructuring and Asset Impairment Charges,” for more information on intangible asset impairment charges recorded in 2019 and 2018.